Evidence map›Paper›PMID 20339154›Full record

Trial reportBMJ (Clinical research ed.)2010

Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.

Giuseppe Mancia, Gianfranco Parati, Miriam Revera, Grzegorz Bilo, Andrea Giuliano, Fabrizio Veglia, Gaetano Crepaldi, Alberto Zanchetti

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMJ (Clinical research ed.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pravastatin for lowering lipids.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  2. Pooled it
  3. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.Journal of clinical hypertension (Greenwich, Conn.) · 2013 · on this map
    Pooled it
  4. Statins for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2013 · on this map
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Observational
  11. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017 · on this map
    Observational
  12. Review
  13. How full is our antihypertensives pipeline?Journal of pharmacology & pharmacotherapeutics · 2012
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Giuseppe ManciaDepartment of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy. giuseppe.mancia@unimib.it
Gianfranco Parati
Miriam Revera
Grzegorz Bilo
Andrea Giuliano
Fabrizio Veglia
Gaetano Crepaldi
Alberto Zanchetti
IRCCS Istituto Auxologico Italiano · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITAzienda Ospedaliera San Gerardo · ITCentro Cardiologico Monzino · ITUniversity of Milano-Bicocca · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring.

designRandomised placebo controlled double blind trial.

setting13 hospitals in Italy

participants508 patients with mild hypertension and hypercholesterolaemia, aged 45 to 70 years.

interventionParticipants were randomised to antihypertensive treatment (hydrochlorothiazide 25 mg once daily or fosinopril 20 mg once daily) with or without the addition of a statin (pravastatin 40 mg once daily). Main outcome measures Clinic and ambulatory blood pressure measured every year throughout an average 2.6 year treatment period.

resultsBoth the group receiving antihypertensive treatment without pravastatin (n=254) (with little change in total cholesterol) and the group receiving antihypertensive treatment with pravastatin (n=253) (with marked and sustained reduction in total cholesterol and low density lipoprotein cholesterol) had a clear cut sustained reduction in clinic measured systolic and diastolic blood pressure as well as in 24 hour, and day and night, systolic and diastolic blood pressure. Pravastatin performed slightly worse than placebo, and between group differences did not exceed 1.9 (95% confidence interval -0.6 to 4.3, P=0.13) mm Hg throughout the treatment period. This was also the case when participants who remained on monotherapy with hydrochlorothiazide or fosinopril throughout the study were considered separately.

conclusionsAdministration of a statin in hypertensive patients in whom blood pressure is effectively reduced by concomitant antihypertensive treatment does not have an additional blood pressure lowering effect. Trial registration BRISQUI_*IV_2004_001 (registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali-National Monitoring Centre on Clinical Research with Medicines).

Indexed as

AgedAnticholesteremic AgentsAntihypertensive AgentsBlood Pressure DeterminationDrug Therapy, CombinationFemaleFosinoprilHumansHydrochlorothiazideHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHypertensionItalyMaleMiddle AgedPravastatinAnticholesteremic AgentsAntihypertensive AgentsFosinoprilHydrochlorothiazideHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatin

Identifiers

PMID20339154
PMCPMC2845783
OpenAlexW2119192927

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.